Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Igen International Inc.

Latest From Igen International Inc.

Biotech's New Breed of IPOs

In assessing the sixteen biotechs making their public debuts over the past six months, investors clearly favor companies specializing in development, not discovery. What's more, investors especially prefer those development firms with late-stage products, lots of cash, and possibly even a sizable out-licensing deal.

BioPharmaceutical Strategy

Deal Statistics Quarterly, Q3 2003

In Vivo presents another installment of our quarterly reivew of dealmaking--in this case July-September 2003. Our data come from Windhover's Strategic Transactions Database. We include medical device financings by deal type; diagnostic financings by industry segment; pharma and biotech alliances by therapeutic category and industry segment; pharma and biotech financings by market segment, and pharma and biotech M&A.

BioPharmaceutical Medical Device

Cepheid Grapples With A Diagnostics Timetable

Anyone looking at investing in diagnostics would do well to consider the cautionary, still-evolving tale of Cepheid as an indication of the complexities inherent in building a new diagnostic enterprise. Cepheid has more going for it than most diagnostic start-ups, including steady revenues from innovative products and an experienced management team with a proven track-record at deal-making. But it faces continual funding issues and a longer-than-expected time frame to profitability.

Medical Device Business Strategies

Roche Pays $1.4 Billion for Igen and Gets Peace of Mind

Roche's $1.4 billion acquisition of Igen left Igen shareholders gleeful and some Roche observers a bit wary of the high price tag. But by ending protracted litigation between the two companies, the deal protects one of Roche Diagnostics' core franchises, the central laboratory business.

Medical Device
See All

Company Information

  • Industry
  • In Vitro Diagnostics